EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis

Fei Gao iD, Sayan Dasgupta, Siavash Pasalar iD, Qi Wang iD, Ricardo Alfaro iD, Delia Pinto-Santini, Thiago S Torres iD, Jorge Sanchez, Javier R Lama iD, Valdilea G Veloso iD, Michal Juraska iD, Robinson Cabello und 5 weitere

Journal of the International AIDS Society · 2026

DOI: 10.1002/jia2.70204 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the International AIDS Society, 2026. Verfasst von Fei Gao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The availability of highly efficacious HIV pre‐exposure prophylaxis (PrEP) makes it unethical or infeasible to conduct inactive/placebo‐controlled trials to evaluate new HIV prevention options. As a result, randomized active‐control non‐inferiority trials are typically employed; however, they require large sample sizes and extended follow‐up. Moreover, their results can be hard to interpret. An alternative approach compares HIV incidence among individuals receiving a new PrEP product to a counterfactual incidence estimate—an estimate of what the HIV incidence would have been in the absence of PrEP.

Methods

We leveraged data from three studies (AMP, Sabes and ImPrEP seroincidence) conducted among men who have sex with men and transgender persons in Lima, Peru, between 2013 and 2022 to estimate the counterfactual HIV incidence for two target populations represented by a clinical trial (AMP) and a non‐interventional cohort study (Sabes). We evaluated three estimation methods: prospective cohort follow‐up, recency testing and rectal gonorrhoea (RG) approaches. These approaches were compared directly using data from the same study, and we further assessed population adjustment approaches by comparing estimates across studies.

Results

All three methods produced consistent HIV incidence estimates when applied to data collected from the same study. ​However, estimates differed when data from external studies were used, even after propensity score (PS) adjustment. For example, estimates for the AMP population using Sabes or ImPrEP data remained higher than the AMP gold‐standard estimate. In contrast, adjusted estimates for the Sabes population using AMP or ImPrEP data were lower than the Sabes follow‐up estimate. These differences underscore the challenges of applying external data and highlight the role of unmeasured population heterogeneity.

Conclusions

Counterfactual HIV incidence estimates can support evaluation of new PrEP agents when direct placebo comparisons are not possible. Estimates from recency‐testing and RG approaches are promising when prospective follow‐up is infeasible, but their validity depends on data quality and population similarity. PS methods improve comparability across populations but cannot fully account for unobserved differences. Triangulating across methods and sources can improve confidence in counterfactual estimates, which should be interpreted with careful attention to population context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisHumansPeruMaleIncidenceAdultFemaleHomosexuality, MaleYoung AdultTransgender PersonsProspective Studies

Stichwörter der Autor:innen

HIV pre‐exposure prophylaxisaviditygonorrhoeahuman immunodeficiency virus (HIV)longitudinal cohortpropensity score weighting

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
  • Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales (CITBM), Lima, Perú.
  • Fundação Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
  • Asociación Civil Impacta Salud y Educación, Lima, Perú.

ORCID-Profile: Fei Gao, Siavash Pasalar, Qi Wang, Ricardo Alfaro, Thiago S Torres, Javier R Lama, Valdilea G Veloso, Michal Juraska, Jorge O Alarcon, Carlos F Caceres, Ann Duerr

Zitieren

APA

Gao, F., Dasgupta, S., Pasalar, S., Wang, Q., Alfaro, R., Pinto-Santini, D., Torres, T. S., Sanchez, J., Lama, J. R., Veloso, V. G., Juraska, M., Cabello, R., Alarcon, J. O., Grinsztejn, B., Caceres, C. F., Rooney, J. F., & Duerr, A. (2026). Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70204

Vancouver

Gao F, Dasgupta S, Pasalar S, Wang Q, Alfaro R, Pinto-Santini D, et al. Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis. Journal of the International AIDS Society. 2026. doi:10.1002/jia2.70204

BibTeX
@article{Gao2026,
  author = {Gao, Fei and Dasgupta, Sayan and Pasalar, Siavash and Wang, Qi and Alfaro, Ricardo and Pinto-Santini, Delia and Torres, Thiago S and Sanchez, Jorge and Lama, Javier R and Veloso, Valdilea G and Juraska, Michal and Cabello, Robinson and Alarcon, Jorge O and Grinsztejn, Beatriz and Caceres, Carlos F and Rooney, James F and Duerr, Ann},
  title = {Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis},
  journal = {Journal of the International AIDS Society},
  year = {2026},
  doi = {10.1002/jia2.70204}
}
Kostenlos starten →